Caliway is a leading brand in the field of medical aesthetics and the development of drugs for chronic inflammatory diseases. Established in 2012, Caliway focuses on developing drugs for conditions that have a market value of over $10 billion and where existing treatment options are ineffective, have significant side effects, or lack approved medications. What sets Caliway apart is their innovative therapies and rigorous testing to enhance the effectiveness and safety of their products.

Their flagship drug, CBL-514 injection, has already shown promising results in clinical trials for non-surgical localized fat reduction and has been granted IND approval by the FDA and TGA. Caliway is also actively researching and developing new drugs for various conditions like skin whitening, anti-aging, obesity, fatty liver, and degenerative joint diseases. Their vision is to become an innovative leader in the international market for medical aesthetics and chronic inflammatory diseases, creating better treatment options and improving quality of life